right time?

Preventing prescription drug abuse and overdose and promoting the wise use of antibiotics have been listed by the Centers for Disease Control and Prevention as two of the five biggest health care priorities for the United States in 2014.

That’s good timing for POH, which is hoping to outlicense its oxymorphone patch either during or after Phase 2 trials this year. The transdermal opioid patch has numerous competitive advantages, but its ability to achieve equivalent efficacy using 75% less opioid than current oral treatment is especially headturning. Also seemingly destined to attract widespread interest for its risk reduction potential is POH’s topical oxycodone patch, which is slated to enter Phase 2 trials in Q1 this year. It tackles hard-to-treat pain without the opioid even entering the bloodstream.

Additionally, with the US prioritising antibiotic reduction in 2014, it surely has to be a good time for attracting US interest in TPM dairy feed, as this recently commercialised product can significantly reduce on-farm antibiotic use.

Could this (finally!)be a case of right products, right space, right time?



http://www.cdc.gov/features/endofyear/

http://globalpublicsquare.blogs.cnn.com/2013/12/18/5-health-challenges-for-2014/